prednisolone

Her symptoms and endoscopic and radiologic abnormalities resolved after discontinuation of pembrolizumab and initiation of oral prednisolone, and steroids were successfully tapered without recurrence. This case highlights a rare but clinically important pattern of ICI-induced pan-airway mucositis, in which lower-airway inflammation may be initially attenuated by inhaled steroids and later become evident after extension to the upper airway; such airway irAEs should be considered in ICI-treated patients presenting with persistent or atypical upper-airway symptoms.

B-cell chronic lymphocytic leukemia (B-CLL) was diagnosed, which in cats is much less frequent than T-CLL. There was a favorable response to alkylating therapy, and the cat survived for 19 months.

Although optic nerve signal changes are an uncommon manifestation of giant cell arteritis (GCA), the neurology team commenced high-dose oral prednisolone (60 mg once daily), considering GCA in the differential diagnosis...Subsequent temporal artery ultrasound findings were consistent with GCA, supporting the diagnosis. This case highlights an unusual radiological presentation of GCA and underscores the importance of early empirical treatment to prevent irreversible visual complications.

P1, N=141, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Recruiting --> Active, not recruiting

Treatment with oral prednisolone, 30 mg daily for 1 week, with a slow taper and dapsone 100 mg once daily was commenced. This case highlights the challenges in managing neutrophilic dermatosis in older patients, particularly when complicated by comorbidities. The patient's evolving clinical picture, including the possibility of rheumatoid arthritis contributing to both her skin and pulmonary manifestations, underscores the importance of a multidisciplinary approach in diagnosing and managing complex dermatological cases in older patients.

He had tried superpotent topical corticosteroids and oral prednisolone, as well as emollients, none of which had improved his symptoms...Tralokinumab was trialled for 12 weeks, as this has a single therapeutic target (interleukin-13), but unfortunately there was no improvement. Following discussion with the immunologists, he was commenced on upadacitinib as this was felt to have a more targeted immunosuppressive effect above agents such as methotrexate and dupilumab. We await his next follow-up appointment to assess response. This case highlights the complexity of treating an immunocompromised individual with immunosuppressive agents, when the cause of their immunosuppression is unknown.

The patient responded favourably to the oral prednisolone therapy...Clinicians should be aware of these potential atypical manifestations to prevent delays in the diagnosis and treatment of VEXAS syndrome. Further research is warranted to delineate the full spectrum of clinical and pathological presentations of VEXAS.

P2, N=80, Completed, Aalborg University Hospital | Recruiting --> Completed

P4, N=13, Completed, University of Arizona | N=90 --> 13

P=N/A, N=120, Recruiting, Cairo University | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025

Adalimumab can effectively control inflammatory responses and reduce recurrence in pediatric TINU syndrome, with a favorable safety profile, thereby providing a novel and promising biologic alternative for steroid-resistant or refractory cases. It is recommended to focus on ocular lesions in patients with tubulointerstitial injuries to avoid missing the diagnosis of TINU syndrome.

P3, N=1074, Not yet recruiting, Te Whatu Ora Health New Zealand Te Toka Tumai Auckland - Starship Children's Hospital